Jamie M Reedy

Dr. Jamie M Reedy

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024 in Global Health Economics and Sustainability
Verified
Journal Article
Open access
PDF file
JRJamie M Reedy
Jamie M Reedy
DPDana Pousty
Dana Pousty
BWBeldeen W. Waliaula
Beldeen W. Waliaula
JMJosephat Maniga
Josephat Maniga
HMHadas Mamane
Hadas Mamane
RMRichard M Mariita
Richard M Mariita
Waterborne diseases pose a significant public health challenge in the Global South, attributed to inadequate access to clean water, insufficient sanitation infrastructure, and poor water treatment systems. These factors contribute to the contamination of water sources with microbial pathogens, placing individuals at a heightened risk of contracting waterborne diseases. Waterborne diseases in the Global South are caused by various bacterial pathogens, parasites, and viruses, with factors such as climate change, water scarcity, and human pollution influencing their proliferation. Vulnerable populations, including children, pregnant women, and immunocompromised individuals, bear the brunt of these diseases, resulting in preventable deaths and hindering socioeconomic development due to health-care costs. Traditional methods for combating these diseases have limitations, leading to the need for alternative water disinfection strategies, such as ultraviolet C light-emitting diodes (UVC LEDs). This review examines both the current state of waterborne diseases in the Global South (i.e., disease prevalence, causes, and public/systemic impacts) and the current landscape of UVC LED technology for water disinfection. Through the lens of this multi-focus review, we also explore the potential widespread implementation of UVC LED technology for water disinfection as a method of combating waterborne diseases to improve public health outcomes. Regulatory frameworks for UVC LED water treatment systems in the Global South remain limited. To address this limitation, we recommend an essential implementation framework that includes legislation, partnerships, sustainability, affordability, industrial and environmental standards, and robust evaluation protocols. Finally, we provide a substantial overview of the future directions and research opportunities in UVC LED technology and water treatment mechanisms aiming for promising public health outcomes. Embracing UVC LED technology can help address persistent disease challenges and improve public health in regions with limited infrastructure, thereby moving closer to achieving the United Nation’s Sustainable Development Goals and emphasizing the significance of universal access to improved WASH (safe water, sanitation, and hygiene) conditions.

23 September 2024 in Hygiene
Verified
Journal Article
Open access
PDF file
JRJamie M Reedy
Jamie M Reedy
TFTheekshana Fernando
Theekshana Fernando
Silas Onyango AwuorSilas Onyango Awuor
Silas Onyango Awuor
EOEric Omori Omwenga
Eric Omori Omwenga
TKTatiana Koutchma
Tatiana Koutchma
RMRichard M Mariita
Richard M Mariita
Emerging antimicrobial-resistant (AMR) Candida auris presents a formidable global health challenge, causing severe healthcare-associated infections (HAIs) with high mortality rates. Its ability to colonize surfaces and resist standard disinfectants undermines traditional hygiene practices, prompting an urgent need for new strategies. Ultraviolet C (UVC) light offers a promising approach with rapid and broad-spectrum germicidal efficacy. This review examines current literature on UVC LED technology in combating C. auris, highlighting its effectiveness, limitations, and applications in healthcare hygiene. UVC light has potent activity against C. auris, with up to 99.9999% inactivation depending on certain conditions such as microbial load, type of organism, surface, environmental, equipment, and UVC radiation factors. UVC LEDs can effectively combat C. auris, driving down healthcare costs and reducing attributable global mortality. Here, we explore implementation strategies for the targeted disinfection of high-risk areas and equipment, air handling units (AHUs), and water treatment systems. Challenges associated with UVC LED disinfection devices in healthcare settings, current performance limitations, and radiation safety are discussed. This will help in optimizing application protocols for effective disinfection and radiation safety. To further strengthen healthcare facility hygiene practices and curb the global spread of C. auris, recommendations for integrating UVC LED disinfection into infection control programs are shared.

26 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
JRJamie M Reedy
Jamie M Reedy
TFTheekshana Fernando
Theekshana Fernando
SASilas O Awuor
Silas O Awuor
EOEric Omori Omwenga
Eric Omori Omwenga
TKTatiana Koutchma
Tatiana Koutchma
RMRichard M Mariita
Richard M Mariita
The emergence of antimicrobial resistance (AMR) Candida auris presents a formidable global health challenge, causing severe healthcare-associated infections with high mortality rates. Its ability to colonize surfaces and resist standard disinfectants undermines traditional hygiene practices, prompting an urgent need for novel strategies. Ultraviolet C (UVC) light offers a promising approach due to its rapid and broad-spectrum germicidal efficacy. This review comprehensively examines the current knowledge of UVC LED technology in combating C. auris, highlighting its effectiveness, limitations, and potential applications in healthcare hygiene. UVC light has potent activity against C. auris, including multidrug-resistant (MDR) strains. UVC can reduce C. auris on contaminated surfaces, aiding in transmission prevention. This review explores implementation strategies, including mobile UVC systems for targeted disinfection of high-risk areas and equipment, integration into air handling units (AHUs) to continuously disinfect recirculating air, and incorporation into water treatment systems. Current limitations in our understanding of UVC safety and effectiveness necessitate further research to optimize application protocols and ensure treatment safety while maintaining efficacy against C. auris. Integrating UVC disinfection technology into infection control programs holds promise for strengthening hygiene practices that will curb the global spread of C. auris and improve patient outcomes.

8 June 2026 in Frontiers in Public Health
Verified
Journal Article
Open access
JRJamie M Reedy
Jamie M Reedy
NBNancy A. Borstelmann
Nancy A. Borstelmann
VGVeda N. Giri
Veda N. Giri
The concerning rise in early onset cancer (EOCs), defined as cancers diagnosed under the age of 50, has called attention to identifying individuals who may benefit from earlier cancer screening. These approaches involve patient-centered discussions to establish a personalized, risk-based screening plan. Important factors to consider when establishing a personalized risk-based cancer screening plan include a comprehensive family and personal cancer history and, if appropriate, genetic testing. Limitations in current cancer screening initiatives, healthcare systems, provider and public awareness, and access issues constrain these efforts. Within this context, we explore the current landscape of cancer screening for younger adults in the United States, describe associated challenges and efforts, and propose strategies for risk-based cancer screening in young adults.

2 December 2025 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
JRJamie M Reedy
Jamie M Reedy
NBNancy A. Borstelmann
Nancy A. Borstelmann
SSSakinah Suttiratana
Sakinah Suttiratana
TSThejal Srikumar
Thejal Srikumar
FFFarah Fasihuddin
Farah Fasihuddin
VGVeda N. Giri
Veda N. Giri
Purpose: Early onset cancers (EOC), defined as cancers diagnosed between the ages of 18 and 49, are on the rise. Younger adults may experience amplified cancer-related challenges. Furthermore, the unique needs of Black/African American (B/AA) and Hispanic/Latine (H/L) adults with EOC have been understudied. Here we report on results from the PROSPER study, which explored the experiences of B/AA and H/L patients with EOC. Methods: Patients diagnosed with early onset breast, gastrointestinal (GI), genitourinary, and gynecological cancers were recruited from a single institution in the Northeastern US. Between February 2024 and April 2024, data were collected from 14 women who participated in both individual interviews (B/AA = 7; H/L = 7) and focus groups (B/AA Group, n = 5; H/L Group, n = 3) in English and/or Spanish. Participants (ages 28–49) were diagnosed with breast ( n = 7), GI ( n = 5), ovarian ( n = 1), or breast and GI ( n = 1) cancer. Interviews were recorded, transcribed, and qualitatively analyzed using modified rapid analysis techniques. Results: Thematic analysis identified challenges across six psychosocial domains spanning the impact of cancer on the patient and family, limited access to information, communication concerns, financial strain, and balancing care with life activities. We also identified unique barriers within our cohort related to clinical care, support needs, and applicable research. Conclusion: Our results support existing literature on the challenges faced by patients with EOCs, while also providing critical insights into the unique experiences of B/AA and H/L women with EOCs. These results inform the development of EOC program strategies.

15 June 2026 in Global South & Sustainable Development
Verified
Journal Article
Open access
PDF file
JRJamie M Reedy
Jamie M Reedy
RMRichard M Mariita
Richard M Mariita
HMHyrine G. Munga
Hyrine G. Munga
BHBritt Hafner
Britt Hafner
The increasing global demand for biopharmaceutical biologics, including vaccines, monoclonal antibodies, enzymes, cytokines, hormones and growth factors, is driven by aging populations, rising cancer incidences, the persistent threat of pandemics such as COVID-19 and endemic infectious diseases such as Tuberculosis and Malaria. While the global biologics market is projected to surpass $1 trillion by 2034, current centralized manufacturing models rely heavily on resource-intensive mammalian systems that pose significant economic and logistical barriers, particularly for the Global South. This review evaluates the imperative for adopting sustainable biomanufacturing pathways to enhance global health security and sovereignty. We critically assess diverse production platforms, ranging from traditional microbial and mammalian cell lines to emerging green systems such as transgenic plants, algae, and cell-free synthesis, against the Triple Bottom Line framework: environmental stewardship, economic viability, and social responsibility. The analysis highlights that while mammalian cells remain the industry standard for complex post-translational modifications (PTMs), plant-based and cell-free platforms offer scalability, reduced carbon footprints, and the potential for decentralized production. Furthermore, the integration of artificial intelligence (AI), digital twins, and single-use technologies is identified as a catalyst for optimizing yield and facilitating net-zero emissions targets. For the Global South, these approaches offer opportunities to overcome resource limitations through localized, low-input platforms. We conclude that transitioning toward resilient, localized, and eco-friendly biomanufacturing is essential to mitigate supply chain vulnerabilities, ensure equitable access to life-saving therapeutics, and safeguard populations against future biological threats.